Trinity Biotech plc
NASDAQ:TRIBMedical - Diagnostics & Research
Healthcare
$5.83 -5.73%
-$0.51 today
- Market cap
- $117.96M
- Beta
- 1.00
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.27
52W Low $8.00High $103.20
Volume 0.00M
Average 1.34M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$5.93M
FY 2025 · Annual
Investing Cash Flow
-$6.22M
FY 2025 · Annual
Financing Cash Flow
$12.05M
FY 2025 · Annual
-58.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 875K | (41.01M) | (24.02M) | (31.79M) | (37.38M) |
| Depreciation & Amortization | 2.74M | 2.33M | 1.78M | 1.87M | 2.68M |
| Deferred Income Tax | (167K) | (192K) | (59K) | 486K | 199K |
| Stock-Based Compensation | 1.1M | 1.76M | 2.07M | 1.32M | 324K |
| Change in Working Capital | (172K) | (1.66M) | (2.69M) | 6.19M | 7.03M |
| Accounts Receivables | 6.24M | (966K) | 1.05M | (2.37M) | 4.92M |
| Inventory | (4.41M) | (877K) | (971K) | (1.74M) | 90K |
| Accounts Payables | (7.59M) | 181K | (2.77M) | 8.19M | 0 |
| Other Working Capital | 5.59M | 7.57M | (478K) | 10.3M | 2.02M |
| Other Non-Cash Items | 8.86M | 37.85M | 11.37M | 17.74M | 21.21M |
| Operating Cash Flow | 13.24M | (921K) | (11.56M) | (4.19M) | (5.93M) |
| Capital Expenditures | (8.69M) | (5.98M) | (803K) | (10.06M) | (6.22M) |
| Acquisitions (Net) | 0 | 0 | 28.16M | (12.9M) | 0 |
| Purchases of Investments | 0 | 0 | (700K) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (6.88M) | (4.88M) | (1.9M) | (9.66M) | (6.14M) |
| Investing Cash Flow | (8.69M) | (5.98M) | 24.76M | (22.97M) | (6.22M) |
| Debt Repayment | (2.94M) | (27.04M) | (7.37M) | 27.67M | 11.81M |
| Common Stock Issued | 0 | 25.34M | 0 | 7.39M | 547K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.08M) | (10.61M) | (8.67M) | (6.25M) | (308K) |
| Financing Cash Flow | (6.02M) | (12.32M) | (16.04M) | 28.81M | 12.05M |
| Effect of Forex Changes | 55K | (112K) | (44K) | (175K) | 71K |
| Net Change in Cash | (1.42M) | (19.33M) | (2.89M) | 1.48M | (29K) |
| Free Cash Flow | 4.55M | (6.9M) | (12.36M) | (14.26M) | (12.15M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$37.4M
+ D&A$2.7M
+ Stock-Based Comp$324.0K
+ Deferred Tax$199.0K
+ Working Capital$7.0M
+ Other Non-Cash$21.2M
= Operating Cash Flow-$5.9M
- Capex-$6.2M
= Free Cash Flow-$12.2M
Analysis
FY2025 free cash flow is -$12.2M. FCF conversion is 32.5% of net income. Operating cash flow was -$5.9M, with capex of -$6.2M. The largest bridge item is Other Non-Cash at $21.2M.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Oct 5, 2026 | |
| 6-K | 6-K filing | Sep 9, 2026 | |
| 6-K | 6-K filing | Sep 8, 2026 |
Does TRIB generate free cash flow?
Trinity Biotech plc (TRIB) generated -$12.15M of free cash flow in fiscal 2025.
How much operating cash flow does TRIB produce?
Operating cash flow was -$5.93M, before capital expenditures of $6.22M.
Continue the stock analysis
Jump to another research area for this company.